Summary 415 million people live with diabetes worldwide, and an estimated 193 million
people have undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients …

Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the
market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 …

Aims To investigate the extent of and factors associated with adherence to Type 2 diabetes
medication. Methods The CINAHL, Embase, International Pharmaceutical Abstracts …

Nonadherence with medication occurs in all chronic medical disorders. It is a particular
challenge in schizophrenia due to the illness's association with social isolation, stigma, and …

Summary Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class
of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes …

Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability
of numerous glucose‐lowering therapies and clear guidelines for T2D management …

Aim To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of
basal insulin Fc (BIF; LY3209590), a fusion protein combining a novel single‐chain insulin …

Background The burden of daily basal insulins often causes hesitancy and delays in the
initiation of insulin therapy. Basal insulin Fc (BIF, insulin efsitora alfa), designed for once …

Many people with type 2 diabetes mellitus (T2DM) fail to achieve glycaemic control promptly
after diagnosis and do not receive timely treatment intensification. This may be in part due to …

Achieving tight glycaemic control early following the diagnosis of type 2 diabetes is key to
optimising clinical outcomes, yet many patients and clinicians are reluctant to initiate and …